David Loew, Ipsen CEO

At #JPM23, an­oth­er rare dis­ease buy­out as Ipsen ac­quires Al­bireo for $952M

Be­fore most JP­Mers arose Mon­day morn­ing, Ipsen an­nounced that it is buy­ing rare dis­ease biotech Al­bireo Phar­ma.

That’s the sec­ond deal dis­closed Mon­day morn­ing, along …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.